Academic Unit Clinical Oncology, Weston Park Hospital, Sheffield S10 2SJ, UK.
Int J Oncol. 2012 Jun;40(6):2075-80. doi: 10.3892/ijo.2012.1387. Epub 2012 Feb 22.
We report the 40-year unselected experience of a UK lymphoma treatment centre. Between 1970 and 2010, 3363 cases of non-Hodgkin lymphoma were managed by the Sheffield Lymphoma Team. Seventy cases of primary thyroid lymphoma were identified during this time. This retrospective review of the clinical and pathological features of patients with thyroid lymphoma comprises one of the largest series conducted in the UK. The series included 57 females and 13 males with a median age at diagnosis of 69.5. The pathological subtypes were diffuse large B-cell lymphoma (DLBCL) in 50 patients, MALT lymphoma in 13, indolent B-cell lymphoma not otherwise specified (NOS) in 6 and T cell lymphoma in one patient. Of the 64 patients fully staged, 53 had Stage IE and 11 Stage IIE disease. Management modalities included surgery, chemotherapy, radiotherapy or combination treatment. Five- year survival rates for DLBCL, MALT lymphoma and indolent B-cell lymphoma NOS were 45%, 62% and 75%, respectively, with a median overall survival of all histological subtypes of 68 months (range 0-148) or 5.7 years. The outcomes of this series confirm previous experience. If treatment is needed after surgery radiotherapy alone is sufficient for Stage I and II low grade thyroid lymphoma. Combination chemotherapy or adequate chemotherapy followed by radiotherapy is warranted in high grade thyroid lymphoma.
我们报告了英国淋巴瘤治疗中心 40 年的无选择经验。1970 年至 2010 年间,谢菲尔德淋巴瘤小组共管理了 3363 例非霍奇金淋巴瘤患者。在此期间,发现了 70 例原发性甲状腺淋巴瘤。对患有甲状腺淋巴瘤的患者的临床和病理特征进行了回顾性研究,这是在英国进行的最大系列研究之一。该系列包括 57 名女性和 13 名男性,中位诊断年龄为 69.5 岁。病理亚型为弥漫性大 B 细胞淋巴瘤(DLBCL)50 例,黏膜相关淋巴组织(MALT)淋巴瘤 13 例,惰性 B 细胞非特指型(NOS)淋巴瘤 6 例,T 细胞淋巴瘤 1 例。在充分分期的 64 例患者中,53 例为 IE 期,11 例为 IIE 期。治疗方式包括手术、化疗、放疗或联合治疗。DLBCL、MALT 淋巴瘤和惰性 B 细胞 NOS 的 5 年生存率分别为 45%、62%和 75%,所有组织学亚型的中位总生存率为 68 个月(范围 0-148)或 5.7 年。该系列的结果证实了以往的经验。如果需要治疗,手术加放疗即可满足 I 期和 II 期低度甲状腺淋巴瘤的需要。高级别甲状腺淋巴瘤需要联合化疗或充分化疗后加放疗。